Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model
| Autor: | Lani Indrawati, John W. Shiver, John E. Macnair, Jon H. Heinrichs, Michael P. Caulfield, Julie M. Skinner, Narahari S. Pujar, Michael A. Winters, Jayme L. Cannon, Walter E. Manger, Yuhua Zhang, Jeffrey T. Blue, Joseph M. Antonello |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Serotype
Heptavalent Pneumococcal Conjugate Vaccine medicine.medical_treatment Drug Evaluation Preclinical medicine.disease_cause complex mixtures Pneumococcal Infections Pneumococcal conjugate vaccine Pneumococcal Vaccines Streptococcus pneumoniae medicine Animals Serotyping Diphtheria toxin Vaccines Conjugate General Veterinary General Immunology and Microbiology business.industry Immunogenicity Polysaccharides Bacterial Public Health Environmental and Occupational Health Antibodies Bacterial Macaca mulatta Virology Vaccination Disease Models Animal Infectious Diseases Immunoglobulin G Antibody Formation Immunology Molecular Medicine Female business Adjuvant medicine.drug |
| Zdroj: | Vaccine. 29:8870-8876 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2011.09.078 |
| Popis: | The incidence of invasive pneumococcal disease (IPD), caused by the approximately 91 serotypes of Streptococcus pneumoniae (PN), varies geographically and temporally as a result of changing epidemiology and vaccination patterns as well as due to regional measurement differences. Prevnar(®) (Pfizer), the first licensed pneumococcal conjugate vaccine (PCV), comprises polysaccharides (PS) from 7 serotypes conjugated to the mutant diphtheria toxin carrier protein, CRM197. In the United States and elsewhere, this vaccine has been highly efficacious in reducing the incidence of IPD caused by vaccine serotypes, however, the incidence of non-vaccine serotypes (e.g., 19A, 22F, and 33F) has increased, resulting in the need for vaccines with higher valencies. In response, 10- and 13-valent PCVs have recently been licensed. To further increase serotype coverage, we have developed a 15-valent PCV containing PS from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F conjugated to CRM197 and formulated on aluminum phosphate adjuvant. Vaccine immunogenicity was evaluated in infant rhesus monkeys since they, like human infants, respond poorly to unconjugated PN PS. Infant (2-3 month old) rhesus monkeys were vaccinated three times with PCV-15 or Prevnar(®) at 2 month intervals, and serotype-specific IgG antibodies were measured using a multiarray electrochemiluminescence (ECL) assay. The results indicate that antibody responses to PCV-15 and Prevnar(®) were comparable for the 7 common serotypes and that post-vaccination responses to PCV-15 were10-fold higher than baseline for the 8 additional serotypes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect